Strs Ohio Buys New Holdings in Vaxcyte, Inc. $PCVX

Key Points

• Strs Ohio has acquired a new position in Vaxcyte, Inc., purchasing 16,600 shares valued at approximately $627,000 in the first quarter.
• Vaxcyte's stock has recently seen a 2.6% decrease, with a current market cap of $4.12 billion and a price-to-earnings ratio of -7.73.
• Analysts have a consensus rating of "Buy" for Vaxcyte, with an average price target of $106.25, indicating potential growth despite recent earnings misses.

Strs Ohio bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 16,600 shares of the company's stock, valued at approximately $627,000.

A number of other large investors have also recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its position in shares of Vaxcyte by 10.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after purchasing an additional 293 shares during the period. Avior Wealth Management LLC raised its stake in shares of Vaxcyte by 5.3% during the 1st quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock worth $257,000 after buying an additional 343 shares in the last quarter. US Bancorp DE raised its holdings in Vaxcyte by 7.2% during the first quarter. US Bancorp DE now owns 5,344 shares of the company's stock worth $202,000 after purchasing an additional 357 shares during the last quarter. Xponance Inc. raised its holdings in Vaxcyte by 4.7% during the first quarter. Xponance Inc. now owns 9,320 shares of the company's stock worth $352,000 after purchasing an additional 415 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Vaxcyte by 1.5% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,635 shares of the company's stock worth $1,119,000 after purchasing an additional 436 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on PCVX. Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a report on Thursday, August 7th. The Goldman Sachs Group began coverage on Vaxcyte in a report on Friday, September 12th. They set a "neutral" rating and a $38.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $106.25.

Vaxcyte Price Performance

Vaxcyte stock traded down $0.14 during mid-day trading on Tuesday, hitting $33.33. 673,064 shares of the company were exchanged, compared to its average volume of 1,770,804. The company has a market capitalization of $4.33 billion, a P/E ratio of -8.10 and a beta of 1.04. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $118.62. The business's 50 day simple moving average is $32.78 and its two-hundred day simple moving average is $37.05.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter last year, the firm earned ($1.10) earnings per share. Equities research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.